Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Heather Hofflich

Osteoporosis · UCSD

View

Dr. Gina Woods

Osteoporosis · UCSD

View

Dr. Austin Baraki

Obesity Medicine · Vineyard Health

View

Dr. Maria Fleseriu

Neuroendocrinology · OHSU Hospital

View

Dr. Priya Jaisinghani

Obesity Medicine · NYU Langone

View

Dr. John Stafford

General Endocrinology · OSUMC

View

Dr. David Cohen

Thyroid · RU

View

Dr. Susan Spratt

Diabetes · Duke

View

Dr. James Findling

Adrenal Diseases · Froedtert

View

Dr. Anupam Kotwal

Thyroid · UNMC

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    BLDr. Benjamin Leder

    Dr. Benjamin Leder

    Endocrinology · Osteoporosis & Bone Metabolism
    Harvard University
    benjaminl

    Research

    3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial

    2026

    Via The Lancet. Diabetes & Endocrinology

    Research

    Comparative bone histomorphometry effects of combined denosumab and teriparatide vs monotherapy in postmenopausal women with osteoporosis: a randomized controlled trial

    2026

    Via Journal of Bone and Mineral Research

    Research

    Safety of low dose inpatient zoledronic acid in acute hip fracture patients with advanced chronic kidney disease

    2026

    Via Journal of Bone and Mineral Research

    Research

    Romosozumab improves microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis

    2025

    Via Journal of Bone and Mineral Research

    Research

    Dose-Specific Effects of Denosumab on Serum Calcium Levels in Patients With Osteoporosis and Various Renal Functions

    2025

    Via The Journal of Clinical Endocrinology and Metabolism

    Research

    The comparative efficacy of 12-mo of alendronate and raloxifene in maintaining denosumab-induced improvement in peripheral volumetric BMD, microarchitecture, and estimated strength

    2025

    Via JBMR Plus

    Research

    Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis

    2024

    Via The Journal of Clinical Endocrinology and Metabolism

    Research

    A Fracture Liaison Service to Address Vitamin D Deficiency for Patients Hospitalized for Osteoporotic Fracture

    2024

    Via Journal of the Endocrine Society

    Research

    Treatment Sequence for Osteoporosis

    2024

    Via Endocrine Practice

    Research

    Zoledronic acid for hip fracture during initial hospitalization

    2024

    Via Journal of Bone and Mineral Research

    Research

    Evaluation of Osteogenic Phenotype in Postmenopausal Women Receiving Anabolic and Antiresorptive Osteoporosis Therapies

    2024

    Via Endocrinology

    Research

    One versus 2 years of alendronate following denosumab: the CARD extension

    2024

    Via Osteoporosis International

    Research

    Safety of Inpatient Zoledronic Acid in the Immediate Postfracture Setting

    2023

    Via The Journal of Clinical Endocrinology and Metabolism

    Research

    The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial

    2023

    Via Osteoporosis International

    Research

    Romosozumab and antiresorptive treatment: the importance of treatment sequence

    2022

    Via Osteoporosis International